Hormone receptor-positive (HR +) BC is more sensitive to CDK4/6 inhibitors given that estrogen boosts CCND1 gene expression which encodes cyclin, contributing to aberrant cell cycle [19–21]. The gene discussed is CDK4; the disease is breast cancer.